Table 2.

Dose modifications recommended for the management of adverse reactions associated with targeted therapies

Agent	Starting dose	First reduction	Second reduction	Third reduction
Everolimus	10 mg once daily	5 mg once daily	Not applicable	Not applicable
Palbociclib	125 mg once daily	100 mg once daily	75 mg once daily	Not applicable
Ribociclib	600 mg once daily	400 mg once daily	200 mg once daily	Not applicable
Abemaciclib
Combination therapy	150 mg twice daily	100 mg twice daily	50 mg twice daily	Not applicable
Monotherapy	200 mg twice daily	150 mg twice daily	100 mg twice daily	50 mg twice daily